Web Desc
Emerging Technologies in Vaccine Discovery and Development
joint with Progress and Pathways Toward an Effective HIV Vaccine
Organizer(s): David Kaslow, Nicholas Jackson and Ann L. Lee
Date: January 28 - February 01, 2018
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Astellas Pharma Inc., Moderna Therapeutics and Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
Immunization remains one of the most effective preventive public health measures, the indirect effects of which are considered a global public good with an impressive net return over costs. Vaccines have contributed to “final public good”: eradication of two viruses and regional elimination of a half dozen or more other pathogens. The development of new vaccines, therefore, would seem an obvious priority area for use-inspired and applied biomedical research, yet the endeavor has become increasingly more challenging. The “easy vaccines have been made” belief, crowded vaccine schedules, escalating costs of full vaccination programs (particularly in cost-sensitive Gavi-eligible countries), and platforms for maternal immunization and Public Health Emergencies of International Concern have all contributed to an urgent need for new or improved approaches to the discovery, development and delivery of vaccines, particularly those that are cheaper, simpler to manufacture, and more convenient to use. The aim of this symposium is to provide a comprehensive survey of emerging tools from the most upstream antigen/vaccine discovery, to active and passive immunization platforms, clinical trials, and manufacturing, formulation and delivery, the desired outcome of which is to provide a forum for an integrated discussion on how best to meet the increasing challenges faced by the scientific community’s efforts in new vaccine development. The Keystone Symposia conference on “Emerging Technologies in Vaccine Discovery and Development” has been specifically paired with the conference on “HIV Vaccines” since discovering, developing and delivering an effective HIV vaccine may be one that benefits most from novel technologies, including new tools in structural immunology and interrogating human immune responses.
Global Health Travel Award Deadline: August 29 2017
Scholarship Deadline: October 4 2017
Discounted Abstract Deadline: October 4 2017
Abstract Deadline: November 2 2017
Discounted Registration Deadline: December 6 2017
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Astellas Pharma Inc.Bill & Melinda Gates FoundationModerna TherapeuticsPfizer Inc.
We gratefully acknowledge additional support for this conference from:
Avanti Polar Lipids, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Sanofi Pasteur
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 28 | 4:00PM - 8:00PM
Arrival and Registration
Room: Van Horne Foyer


Sunday, January 28 | 6:00PM - 8:00PM
Welcome Mixer
Room: Van Horne Foyer
No registration fees are used to fund alcohol served at this function.

Monday, January 29 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Monday, January 29 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Van Horne C

Speaker 1 of 2
* David C. Kaslow, PATH, USA

Monday, January 29 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Van Horne C

Speaker 2 of 2
Penny M. Heaton, Bill & Melinda Gates Medical Research Institute, USA
Introducing the Gates Medical Research Institute: A Vision for Accelerating Translational Development

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 1 of 7
* Pamela J. Bjorkman, California Institute of Technology, USA

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 2 of 7
Tobias R. Kollmann, Telethon Kids Institute, Australia
Decoding the Human Immune System to Accelerate Vaccine Development

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C


Coffee Break

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 4 of 7
Simon Delagrave, Sanofi Pasteur, USA
Novel Antigen Design and Functional Immune Assessments

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 5 of 7
Rafick Sekaly, Emory University, USA
Systems Biology and Vaccine Discovery

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 6 of 7
Sarah F. Andrews, National Institutes of Health, USA
Short Talk: Single-Cell Characterization of the Recall and de novo Responses in Humans to Influenza Hemagglutinin

Monday, January 29 | 9:00AM - 11:30AM
New Tools in Antigen/Vaccine Discovery
Room: Van Horne C

Speaker 7 of 7
Hana Golding, US Food and Drug Administration, USA
Short Talk: Impact of AS03 Adjuvant on Antibody Repertoires and Affinity Maturation Against H5N1 Pandemic Influenza
Vaccines and Heterologous Neutralization


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 6
Dennis R. Burton, The Scripps Research Institute, USA
Neutralizing HIV Antibodies and Protection


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B


Coffee Break


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 3 of 6
Barton F. Haynes, Duke University Medical Center, USA
Host Controls of Broadly Neutralizing Antibodies


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 6
* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Early Clinical Concepts to Advanced Stage HIV Vaccine Studies


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 5 of 6
Daniel Stieh, Johnson & Johnson, Netherlands
Short Talk: Interim Immunogenicity Analysis of TRAVERSE: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind phase 1/2a Study in HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of Two Different Prime/Boost Regimens


Monday, January 29 | 9:00AM - 11:30AM
Laying the Foundation for an HIV Vaccine
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 6 of 6
Tomas Hanke, University of Oxford, UK
Short Talk: Clinical Development of the First -Generation Conserved Region T Cell Vaccines


Monday, January 29 | 11:30AM - 5:00PM
On Own for Lunch


Monday, January 29 | 11:30AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Monday, January 29 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 1 of 8
* Richard Malley, Boston Children's Hospital, USA

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 2 of 8
Lenny Moise, EpiVax, USA
Immune Engineered H7N9 Influenza Hemagglutinin Overcomes Poor Vaccine Immunogenicity

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 3 of 8
Clare N. Burn, Albert Einstein College of Medicine, USA
An HSV Vaccine Candidate Deleted in Glycoprotein D Elicits High Titer Fc?RIV-Activating Antibodies that Protect
against HSV Challenge: A Role for HVEM in Functional Immune Responses


Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 4 of 8
Ian Francis, Boston University, USA
Neisseria Gonorrhoeae Outer Membrane Vesicles Lacking RMP Show Promise as a Vaccine Antigen

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 5 of 8
Raphael Simon, University of Maryland School of Medicine, USA
Preclinical Development of a Glycoconjugate Vaccine for Sub-Saharan Africa to Prevent Typhoid and Invasive Nontyphoidal Salmonella Disease

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 6 of 8
Emmanuel Amlabu, University of Ghana, Ghana
Functional Characterization of Plasmodium Falciparum Surface Related Protein (PfSRP) as a Potential Blood-Stage Vaccine Target

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 7 of 8
Mariette Barbier, West Virginia University, USA
Development of Vaccines against P. Aeruginosa based on Iron Acquisition

Monday, January 29 | 2:30PM - 4:30PM
Workshop 1: Assessing Immunogenicity in Animals to Predict O
utcomes in Humans
Room: Van Horne C

Speaker 8 of 8
Jian-Dong Huang, University of Hong Kong, China
Combination of Multiple Antigens are Essential for the Development of a Novel Vaccine Against Staphylococcus aureus Infection

Monday, January 29 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Monday, January 29 | 5:00PM - 7:00PM
Structural Immunology Guiding Vaccine Development (Joint)
Room: Van Horne A/B

Speaker 1 of 4
* Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Monday, January 29 | 5:00PM - 7:00PM
Structural Immunology Guiding Vaccine Development (Joint)
Room: Van Horne A/B

Speaker 2 of 4
Jason S. McLellan, University of Texas at Austin, USA
Structure-Based Vaccine Design for Class I Viral Fusion Glycoproteins

Monday, January 29 | 5:00PM - 7:00PM
Structural Immunology Guiding Vaccine Development (Joint)
Room: Van Horne A/B

Speaker 3 of 4
Andrew B. Ward, The Scripps Research Institute, USA
Using Structures to Guide Env Immunogen Design and Redesign

Monday, January 29 | 5:00PM - 7:00PM
Structural Immunology Guiding Vaccine Development (Joint)
Room: Van Horne A/B

Speaker 4 of 4
Walther Mothes, Yale University School of Medicine, USA
Short Talk: Associating HIV-1 Env Trimer Structures with Functional Env Conformational States by smFRET Analysis

Monday, January 29 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Monday, January 29 | 7:30PM - 10:00PM
Poster Session 1
Room: Mezzanine 2


Tuesday, January 30 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 1 of 9
* Louis J. Picker, Oregon Health & Science University, USA

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 2 of 9
Klaus Früh, Oregon Health & Science University, USA
CMV-Vectored Vaccines for Eliciting Cellular Immunity

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 3 of 9
Justin Moran, Pfizer Inc., USA
Multi-Component Vaccines Are the Future but Pose Development Challenges

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C


Coffee Break

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 5 of 9
Richard Malley, Boston Children's Hospital, USA
Generating Broad B- and T-Cell Immunity via the Multiple Antigen-Presenting System (MAPS)

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 6 of 9
Christine Shaw, Moderna, USA
Targeting Viral Pathogens with mRNA-Based Vaccines

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 7 of 9
Tong-Ming Fu, Merck Research Laboratories, USA
Short Talk: A Replication-Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 8 of 9
Nadia Oreshkova, Leiden University Medical Center, Netherlands
Short Talk: Engineering Yellow Fever Virus 17D-based RNA Replicons into an Innovative DNA-Launched Vaccine Vector Platform

Tuesday, January 30 | 8:00AM - 11:30AM
New Platforms for Active Immunization
Room: Van Horne C

Speaker 9 of 9
Jean-Philippe Julien, Hospital for Sick Children Research Institute, Canada
Short Talk: Structural Studies of Human Antibody Responses to Malaria Vaccine Antigen PfCSP

Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 7
* Shane Crotty, La Jolla Institute for Immunology, USA
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 7
Gabriel D. Victora, Rockefeller University, USA
Clonal and Cellular Dynamics of Germinal Center Selection


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B


Coffee Break


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 7
Facundo D. Batista, Massachusetts Institute of Technology and Harvard University, USA
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 5 of 7
Kimberly M. Cirelli, La Jolla Institute for Immunology, USA
Short Talk: Sustained Delivery Immunization Enhances Germinal Center and Antibody Responses to Env in rhesus macaques


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 6 of 7
Omolara Olujimi Baiyegunhi, University of KwaZulu-Natal, South Africa
Short Talk: Early Initiation of Antiretroviral Therapy during Hyperacute HIV-1 Infection Preserves T Follicular Helper Cell Function


Tuesday, January 30 | 8:00AM - 11:00AM
Germinal Centers, B/T Cell Interactions
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 7 of 7
Ben Read, Massachusetts Institute of Technology, USA
Short Talk: Nanoparticle Delivery, Glycosylation and Host Complement Target Env Immunogens to the Germinal Center


Tuesday, January 30 | 11:15AM - 1:00PM
Hands-On Computer Session on Los Alamos Sequence Database
This session is from HIV Vaccines
Room: Baron Shaughnessy
HIV Database Workshop presented by Los Alamos National Laboratory staff. Topics include:
- HIV Sequence Database
- Bioinformatics tools that have general application

Users can register for either or both workshops. Bring your own laptop.


Tuesday, January 30 | 11:30AM - 5:00PM
On Own for Lunch


Tuesday, January 30 | 11:30AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Tuesday, January 30 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 1 of 7
* David C. Kaslow, PATH, USA
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 2 of 7
Christine Dahlke, University Medical Center Hamburg-Eppendorf, Germany
Human miRNome Profiling Identifies a MicroRNA Signature Induced by the Ebola Vaccine rVSV-EBOV

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 3 of 7
Tulika Singh, Duke University, USA
Transplacental Transfer of IgG in the Setting of Zika Virus Infection during Pregnancy

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 4 of 7
Neal Scott Van Hoeven, Infectious Disease Research Institute, USA
Development of a Flexible Replicating Viral RNA Vaccine Platform and Generation of a Candidate Vaccine for Zika Virus

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 5 of 7
Emma M. Kennedy, Public Health England, UK
Development of a Vaccine for Lassa Fever using Modified Vaccinia Ankara Virus as a Vector

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 6 of 7
Nianshuang Wang, University of Texas at Austin, USA
Structure-Based Design of Prefusion Coronavirus Spikes with Enhanced Expression, Stability and Immunogenicity

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Epidemic Preparedness Innovation
Room: Van Horne C

Speaker 7 of 7
Jingjing Jiang, Inovio Pharmaceuticals, USA
Immunogenicity of a Multivalent Mosquito-Borne Virus DNA Vaccine in Non-Human Primates

Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 10
* Marie Pancera, Fred Hutchinson Cancer Research Center, USA


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 10
* Michael Farzan, The Scripps Research Institute, USA


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 3 of 10
Christopher A. Cottrell, The Scripps Research Institute, USA
Using High-Resolution Cryo-Electron Microscopy to Guide Iterative Structure-Based HIV Vaccine Design


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 10
Christopher O. Barnes, California Institute of Technology, USA
Structural Characterization of a Highly Potent V3-Targeting Broadly Neutralizing Antibody Bound to Natively-Glycosylated HIV-1 Envelope


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 5 of 10
Jose Maximiliano Medina-Ramírez, University of Amsterdam, Netherlands
Sequential Vaccination Regimens Based on Multiclade Germline-Targeting Trimers and Affinity Intermediates to Guide bNAb Development


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 6 of 10
Jason J. Gorman, NIAID, National Institutes of Health, USA
Stabilization of Soluble SIV Envelope Trimers


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 7 of 10
Wilton B. Williams, Duke University, USA
SHIV-CH848 Infection of Rhesus Macaques Recapitulates HIV-1 Env-Antibody Co-Evolution of Humans


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 8 of 10
Tara A. Bancroft, Fred Hutchinson Cancer Research Center, USA
Detection and in vivo Activation of Naive B Cells Expressing Putative Germline Precursors of a Neutralizing Antibody using Anti-Idiotypes


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 9 of 10
Devin Sok, International AIDS Vaccine Initiative, USA
Non-human Primate Pharmacokinetics Evaluation of Broadly Neutralizing Antibodies Isolated from Cow Immunizations


Tuesday, January 30 | 2:30PM - 4:30PM
Workshop 1: Laying the Groundwork for Vaccine Design
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 10 of 10
Claudia Cicala, NIAID, National Institutes of Health, USA
Select gp120 V2 Domain Specific Antibodies Derived from HIV and SIV Infection and Vaccination Inhibit gp120 Binding to Integrin a4ß7


Tuesday, January 30 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 1 of 6
* Charles Richter King, PATH, Malaria Vaccine Initiative, USA

Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 2 of 6
JoAnn A. Suzich, AstraZeneca, USA
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis

Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 3 of 6
Alejandro Balazs, Massachusetts General Hospital, USA
Development of Vectored Immunotherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies

Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 4 of 6
Amar Kumar Garg, Indian Institute of Science, India
Short Talk: Stochastic Simulation of Affinity Maturation in Germinal Centers Suggest Optimal Passive Immunization Protocols

Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 5 of 6
Steven E. Bosinger, Emory University, USA
Short Talk: BALDR - A Computational Pipeline for Linking Paired Immunoglobulin Heavy and Light Chain to Gene Expression for Single-Cells in Vaccine Studies

Tuesday, January 30 | 5:00PM - 7:00PM
New Platforms for Passive Immunization
Room: Van Horne C

Speaker 6 of 6
Cody S. Nelson, Duke University, USA
Short Talk: HCMV Glycoprotein B Vaccine Efficacy Likely Mediated by Non-Neutralizing Antibody Effector Functions

Tuesday, January 30 | 5:00PM - 7:00PM
Model Systems for HIV Vaccine Development
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 4
* George M. Shaw, University of Pennsylvania, USA
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies


Tuesday, January 30 | 5:00PM - 7:00PM
Model Systems for HIV Vaccine Development
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 4
Pia Dosenovic, Karolinska Institutet, Sweden
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System


Tuesday, January 30 | 5:00PM - 7:00PM
Model Systems for HIV Vaccine Development
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 3 of 4
Andres Finzi, CRCHUM, Université de Montréal, Canada
Impact of Env Conformation on ADCC Responses


Tuesday, January 30 | 5:00PM - 7:00PM
Model Systems for HIV Vaccine Development
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 4
Ann J. Hessell, Oregon Health & Science University, USA
Short Talk: Targeting V1V2 Epitopes for the Development of an Effective HIV Vaccine


Tuesday, January 30 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Tuesday, January 30 | 7:30PM - 10:00PM
Poster Session 2
Room: Mezzanine 2


Wednesday, January 31 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B

Speaker 1 of 6
* Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Computational Tools for Antigen Design

Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B

Speaker 2 of 6
Mohammad M. Sajadi, University of Maryland School of Medicine, USA
The Circulating Antibody Repertoire: Tools of the Trade

Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B


Coffee Break

Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B

Speaker 4 of 6
Louis J. Picker, Oregon Health & Science University, USA
Immune Programming with CMV Vectors

Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B

Speaker 5 of 6
Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
Characterizing the Cellular and Humoral Response of Human Volunteers following Dengue Vaccination and Challenge in a Dengue Controlled Human Infection Model

Wednesday, January 31 | 8:00AM - 11:00AM
New Tools in Interrogating Human Immune Responses (Joint)
Room: Van Horne A/B

Speaker 6 of 6
Ian Setliff, Vanderbilt Vaccine Center, USA
Short Talk: Identification of Public Antibody Clonotypes in HIV-1 Infection

Wednesday, January 31 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, January 31 | 11:00AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Wednesday, January 31 | 11:30AM - 1:00PM
Hands-On Computer Session on Los Alamos Immunology Database
This session is from HIV Vaccines
Room: Baron Shaughnessy
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include:
- HIV Immunology Database
- Immunology and vaccine design tools that have general application

Users can register for either or both workshops. Bring your own laptop.


Wednesday, January 31 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 10
* Nancy L. Haigwood, Oregon Health & Science University, USA


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 10
* Alejandro Balazs, Massachusetts General Hospital, USA


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 3 of 10
Andrew Jones, Emory University, USA
Sublingual and Buccal Delivery of MVA/Protein HIV Vaccination with a Needle-Free Injector Induces Robust Systemic and Mucosal Antibody Responses in Rhesus Macaques


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 10
Barbara K. Felber, NCI, National Institutes of Health, USA
DNA+Protein HIV Vaccine Protection against SHIV Challenge upon Same-Site Administration in Macaques


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 5 of 10
Matthias Georg Pauthner, The Scripps Research Institute, USA
Vaccine-Induced Protection from Autologous Tier 2 SHIV-BG505 Challenge


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 6 of 10
Keyun Wang, NIAID, National Institutes of Health, USA
Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 7 of 10
Kristen W. Cohen, Fred Hutchinson Cancer Research Center, USA
Expansion of VH1-2*02 Env-Specific B Cells by Vaccination


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 8 of 10
Tongqing Zhou, NIAID, National Institutes of Health, USA
Priming with Glycan-deleted HIV-1 Env Trimers and Sequential Boosting with Glycan-Restored Immunogens Induces Immune Responses that Neutralize Diverse Tier-2 Viruses


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 9 of 10
Daniel P. Leaman, The Scripps Research Institute, USA
Membrane Env Liposomes as a Platform for Immunization with Membrane-Incorporated HIV Env Spikes


Wednesday, January 31 | 2:30PM - 4:30PM
Workshop 2: Clinical and Preclinical Vaccine Studies
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 10 of 10
Jon Steichen, The Scripps Research Institute, USA
Germline-Targeting for HCDR3-Dependent Broadly Neutralizing Antibodies


Wednesday, January 31 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Wednesday, January 31 | 5:00PM - 7:00PM
New Approaches in Vaccine Clinical Trial Design
Room: Van Horne C

Speaker 1 of 5
* Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA

Wednesday, January 31 | 5:00PM - 7:00PM
New Approaches in Vaccine Clinical Trial Design
Room: Van Horne C

Speaker 2 of 5
Thomas Evans, TomegaVax, USA
Mathematical Modeling of Human Immune Responses to Design more Efficient Vaccine Clinical Development

Wednesday, January 31 | 5:00PM - 7:00PM
New Approaches in Vaccine Clinical Trial Design
Room: Van Horne C

Speaker 3 of 5
Ashley J. Birkett, PATH, USA
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts

Wednesday, January 31 | 5:00PM - 7:00PM
New Approaches in Vaccine Clinical Trial Design
Room: Van Horne C

Speaker 4 of 5
Chris Gast, PATH, USA
Novel and More Efficient Vaccine Clinical Trials using Adaptive Designs

Wednesday, January 31 | 5:00PM - 7:00PM
New Approaches in Vaccine Clinical Trial Design
Room: Van Horne C

Speaker 5 of 5
Maryam Mukhamedova, NIAID, National Institutes of Health, USA
Short Talk: RSV Antibody Repertoire Analysis from Memory B Cells from RSV DS-Cav1-Vaccinated Adult Volunteers

Wednesday, January 31 | 5:00PM - 7:15PM
New Insights into HIV/SIV Env Biology and the Function of No
n-Neutralizing Antibodies
This session is from HIV Vaccines

Room: Van Horne A/B

Speaker 1 of 5
Stuart J. Neil, King's College London, UK
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction


Wednesday, January 31 | 5:00PM - 7:15PM
New Insights into HIV/SIV Env Biology and the Function of No
n-Neutralizing Antibodies
This session is from HIV Vaccines

Room: Van Horne A/B

Speaker 2 of 5
* Beatrice H. Hahn, University of Pennsylvania, USA
SIVcpz and SIVgor Env-Based Immunogens


Wednesday, January 31 | 5:00PM - 7:15PM
New Insights into HIV/SIV Env Biology and the Function of No
n-Neutralizing Antibodies
This session is from HIV Vaccines

Room: Van Horne A/B

Speaker 3 of 5
Michael Farzan, The Scripps Research Institute, USA
eCD4-Ig Unmasks Epitopes of Non-neutralizing Antibodies in Patient Serum to Mediate Potent ADCC


Wednesday, January 31 | 5:00PM - 7:15PM
New Insights into HIV/SIV Env Biology and the Function of No
n-Neutralizing Antibodies
This session is from HIV Vaccines

Room: Van Horne A/B

Speaker 4 of 5
Lars Hangartner, The Scripps Research Institute, USA
Short Talk: Low-Dose PGT121 Sterilely Protects Macaques in an Fc?R-independent Manner from Vaginal Challenge with SHIVSF163P3


Wednesday, January 31 | 5:00PM - 7:15PM
New Insights into HIV/SIV Env Biology and the Function of No
n-Neutralizing Antibodies
This session is from HIV Vaccines

Room: Van Horne A/B

Speaker 5 of 5
Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Induction with V1V2-scaffold Protein Immunogens of Cross-Clade Reactive V2-specific Effector Antibodies with Fc-Mediated Antiviral Functions


Wednesday, January 31 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Wednesday, January 31 | 7:30PM - 10:00PM
Poster Session 3
Room: Mezzanine 2


Thursday, February 01 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 1 of 8
Sangeetha L. Sagar, Sanofi Pasteur, USA
Advances and Challenges in Vaccine Development and Manufacture

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 2 of 8
* Andrew Lees, Fina Biosolutoins, USA
Talk Title to be Announced

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C


Coffee Break

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 4 of 8
James N. Thomas, Just Biotherapeutics, USA
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle Income Countries

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 5 of 8
Phillip W. Berman, University of California, Santa Cruz, USA
Breaking the Logjam in HIV Envelope Vaccine Production: Robotics and Gene Editing to Improve Upstream and
Downstream Manufacturing Processes


Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 6 of 8
Mark S. Fife, Pirbright Institute, UK
Short Talk: Gene Knockout Technology of Chicken Interferon Inducible Transmembrane Proteins (chIFITMs) for Increased Vaccine Production

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 7 of 8
Gabriel Byrne, University of California, Santa Cruz, USA
Short Talk: Use of Gene Editing for the Development of an Mgat1 Deficient CHO Cell Line Suitable for GMP Manufacturing of HIV Vaccines

Thursday, February 01 | 8:00AM - 11:30AM
New Tools in Vaccine Manufacturing and Product Analytics
Room: Van Horne C

Speaker 8 of 8
Caroline B. Kjaerulff Mathiesen, Metropolitan University College, University of Copenhagen, Denmark
Short Talk: Genetically Engineered Cell Factories Produce Glycoengineered Vaccines that Target Antigen Presenting Cells and Alter Immunity

Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 7
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, USA
Targeted Expansion and Maturation of bNAb B Cell Precursors


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 7
* John R. Mascola, NIAID, National Institutes of Health, USA
Strategies to Elicit HIV-1 Fusion Peptide Directed Neutralizing Antibodies


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B


Coffee Break


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 7
William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 5 of 7
Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Native-Like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 6 of 7
Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Short Talk: Development of Three MPER-directed Neutralizing Antibody Lineages in an HIV Infected Individual


Thursday, February 01 | 8:00AM - 11:15AM
Induction of Broad Neutralizing Antibodies by Vaccination
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 7 of 7
Kevin O. Saunders, Duke University, USA
Short Talk: Modification of HIV Env Glycosylation Augments Binding to Unmutated Common Ancestor and Intermediate Antibodies of V3-Glycan Broadly Neutralizing Antibody Lineages


Thursday, February 01 | 11:30AM - 5:00PM
On Own for Lunch


Thursday, February 01 | 1:00PM - 2:30PM
Meet the Editors Panel (Joint)
Room: Van Horne A/B
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors
Speaker 1 of 4
Sonja Schmid, Nature Publishing Group, USA

Thursday, February 01 | 1:00PM - 2:30PM
Meet the Editors Panel (Joint)
Room: Van Horne A/B
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors
Speaker 2 of 4
Kavitha Scranton, Immunity, USA

Thursday, February 01 | 1:00PM - 2:30PM
Meet the Editors Panel (Joint)
Room: Van Horne A/B
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors
Speaker 3 of 4
Andrew J. Rennekamp, Cell Press, USA

Thursday, February 01 | 1:00PM - 2:30PM
Meet the Editors Panel (Joint)
Room: Van Horne A/B
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors
Speaker 4 of 4
Lindsey Pujanandez, Science Translational Medicine, USA

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 1 of 9
* Tong-Ming Fu, Merck Research Laboratories, USA

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 2 of 9
Bruno Emanuel Correia, École Polytechnique Fédérale de Lausanne, Switzerland
On the Development of Precision Vaccines through Epitope-Focused Immunogens: A Case Study on RSV

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 3 of 9
Lan Zhang, Merck, USA
Design and Characterization of an Improved Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 4 of 9
Michael J. Moser, FluGen, Inc., USA
Single-Replication Influenza B Virus Vaccine BM2SR Provides Sterilizing Immunity and Cross-Lineage Protection by Inducing both Cellular and Cytokine Responses in Mice

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 5 of 9
Masaru Kanekiyo, NIAID, National Institutes of Health, USA
Targeting the Conserved Stem Supersite on Influenza Virus Hemagglutinin by Human Ighd-Encoded Innate-Like Element

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 6 of 9
Rahul Shukla, International Centre for Genetic Engineering and Biotechnology, India
“Four-in-One” Envelope-based mosaic VLPs Elicit Tetravalent Neutralizing Antibody Response Devoid of Enhancement Potential in Mice

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 7 of 9
Guangzu Zhao, University of Queensland, Australia
Self-Adjuvanting and Self-Assembling Lipid Core Peptide Vaccines against Human Hookworm Parasite

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 8 of 9
Wessam Melik, Orebro University, Sweden
Development of an Edible TBEV Vaccine

Thursday, February 01 | 2:30PM - 4:30PM
Workshop 3: How Best to Meet the Increasing Challenges Faced
in Vaccine Development
Room: Van Horne C

Speaker 9 of 9
Rocio Jimenez-Martinez, Griffith University-QIMRB, Australia
Investigating Venom Derived Molecules that Augment Human Immune Function

Thursday, February 01 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Thursday, February 01 | 5:00PM - 6:45PM
New Tools in Vaccine Formulation and Delivery
Room: Van Horne C

Speaker 1 of 4
* David C. Kaslow, PATH, USA

Thursday, February 01 | 5:00PM - 6:45PM
New Tools in Vaccine Formulation and Delivery
Room: Van Horne C

Speaker 2 of 4
Nathalie Garçon, Bioaster, France
Adjuvants in Vaccines: From Aluminium to AS01: What Path for their Development and Licensure?

Thursday, February 01 | 5:00PM - 6:45PM
New Tools in Vaccine Formulation and Delivery
Room: Van Horne C

Speaker 3 of 4
Rhea N. Coler, Infectious Disease Research Institute, USA
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations

Thursday, February 01 | 5:00PM - 6:45PM
New Tools in Vaccine Formulation and Delivery
Room: Van Horne C

Speaker 4 of 4
Patrick M. Reeves, Massachusetts General Hospital, USA
Accelerated Development of a T Cell-Based Vaccine for Q Fever

Thursday, February 01 | 5:00PM - 7:00PM
Antibodies as Immunoprophylaxis and Treatment
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 1 of 4
Marina F. Caskey, Rockefeller University, USA
Effects of Potent Broad Neutralizing Antibody Combinations in Humans


Thursday, February 01 | 5:00PM - 7:00PM
Antibodies as Immunoprophylaxis and Treatment
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 2 of 4
Julie Ledgerwood, NIAID, National Institutes of Health, USA
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials


Thursday, February 01 | 5:00PM - 7:00PM
Antibodies as Immunoprophylaxis and Treatment
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 3 of 4
* David D. Ho, Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center, USA
Engineering HIV-Neutralizing Bispecific Antibodies


Thursday, February 01 | 5:00PM - 7:00PM
Antibodies as Immunoprophylaxis and Treatment
This session is from HIV Vaccines
Room: Van Horne A/B

Speaker 4 of 4
Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Recognition by Antibody of All Major Exposed Regions of the Prefusion Closed HIV-1 Env Trimer


Thursday, February 01 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Van Horne C


Thursday, February 01 | 7:00PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from HIV Vaccines
Room: Van Horne A/B


Thursday, February 01 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Thursday, February 01 | 8:00PM - 11:00PM
Entertainment
Room: Alberta/New Brunswick
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, February 01 | 8:00PM - 11:00PM
Cash Bar
Room: Alberta/New Brunswick


Friday, February 02 | 10:24AM - 10:24AM
Departure


*Session Chair.